Hidroxy 250 Injection contains Hydroxyprogesterone acetate at a concentration of 250 mg/ml, a synthetic derivative of the naturally occurring hormone progesterone. It is primarily indicated for the prevention of preterm birth in women with a history of spontaneous preterm delivery. Hydroxyprogesterone exerts its therapeutic effect by modulating the hormonal environment to maintain uterine quiescence and reduce uterine contractility. Administered via intramuscular injection, Hidroxy 250 Injection ensures sustained release and bioavailability of the active compound. The dosage and duration of treatment should be individualized based on clinical response and patient history, typically initiated between 16 and 20 weeks of gestation and continued until 37 weeks or delivery. Contraindications include known hypersensitivity to hydroxyprogesterone or any component of the formulation, active thrombophlebitis, thromboembolic disorders, and certain hormone-sensitive malignancies. Caution is advised in patients with hepatic impairment, cardiovascular disease, or diabetes mellitus. Common adverse effects may include injection site reactions, fluid retention, and mild gastrointestinal disturbances. Due to its hormonal activity, monitoring for signs of thromboembolism is recommended. Hidroxy 250 Injection should be used under strict medical supervision with appropriate patient counseling regarding potential risks and benefits.